Destiny Pharma plc("Destiny Pharma" or "the Company") Announces publication of XF-73 nasal gel Phase 2 data in leading US journal Infection Control & Hospital Epidemiology Demonstrates significant reduction of nasal S. aureus in preoperative cardiac surgery patients Brighton, United Kingdo.
The American Heart Association (AHA) Scientific Sessions 2022 in Chicago, and virtually, is set for November 5-7 at McCormick Place. Highly-anticipated clinical trial breakthroughs and discoveries of the year will be offered in both late-breaking scientific sessions and featured science sessions.
/PRNewswire/ CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using.